Why Timelines Break Down in Rare Kidney Drug Development
Rare kidney trials miss enrollment timelines for the same reason most clinical projects fail: eligible patients reach sites too slowly and in insufficient numbers. In several nephrology indications, this bottleneck is tightening, making early intervention the difference between momentum and delay.
